Skip to main content
Article thumbnail
Location of Repository

Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.

By E. Jonsson, H. Fridborg, K. Csóka, S. Dhar, C. Sundström, P. Nygren and R. Larsson


The cytotoxic activity and cross-resistance pattern of the novel topoisomerase I inhibitor topotecan (Topo) were investigated in ten cell lines, representing different mechanisms of cytotoxic drug resistance, and in 218 fresh human tumour samples using the fluorometric microculture cytotoxicity assay (FMCA). Resistance to Topo in the cell lines was associated with expression of the multidrug resistance-associated protein (MRP), whereas the cell lines with P-glycoprotein (P-gp), topoisomerase II and glutathione-associated resistance did not show decreased sensitivity to the drug. Topo was more active in haematological than in solid tumour samples, but substantial activity was observed in carcinomas of the ovary and breast, sarcoma and childhood solid tumours. Cross-resistance to standard drugs representing different mechanisms of action was generally low in patient cells. The effect of Topo was better after longer exposure, but this time-dependent effect was largely abolished when adjustment for in vitro exposure was made. Topo showed activity both in proliferative and non-proliferative cell systems. The results indicate that Topo is insensitive to major mechanisms of resistance except for MRP. Proliferation does not seem to be necessary for the effect of Topo, and no superiority for protracted dosing schedules was observed. The results also suggest that, for example, leukaemias, lymphomas, sarcomas and childhood solid tumours may be suitable targets for future phase II trials

Topics: Research Article
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1995). Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    2. (1996). Current perspectives on camptothecins in cancer treatment.
    3. (1992). Effect of p-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    4. (1995). Evaluation of the cytotoxic activity ofgemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
    5. (1992). Laboratory determination ofchemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA).
    6. (1989). Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. JNatl Cancer Inst 81: 1732-1735 Uckun
    7. (1994). Phase II study of topotecan in pretreated small cell lung cancer (SCLC). Proc Annu MeetAnm Soc Clin Oncol 13: A1116 Botling
    8. (1994). Phase II study oftopotecan in extensive stage small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol 13: A330 Sliutz

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.